Nouryon reduces carbon dioxide emissions with additional bio-steam supply
Nouryon will increase the use of bio-steam at its salt production at Hengelo, in the Netherlands, making the production more sustainable and reducing carbon dioxide emissions.
AFYREN secures over 60 million euros of financing to move into its industrial development phase
In order to offer industrial firms a reliable alternative to using acids based on oil derivatives, AFYREN has confirmed the production of bio-based organic acids on a pre-industrial scale for use with multiple applications. Today, AFYREN is launching its industrial development phase after securing total financing of 60 million euros, including a 21 million euro capital increase.
Braskem and Haldor Topsoe start up demo unit for developing renewable MEG
The mechanical completion of the innovative first process step of the demonstration plant is the first milestone to be achieved by Braskem and Haldor Topsoe’s partnership to validate the MOSAIK™ sugar-to-biochemicals solution for production of cost-competitive bio-based MEG (monoethylene glycol). Currently, MEG is made from fossil-based feedstocks, such as naphtha, gas or coal. The demonstration plant is expected to produce more than 100 tons per year of glycolaldehyde, the precursor for MEG, when it begins operation on March 1, 2019. MEG is a key component of PET plastic used for food packaging, especially bottles, and polyester fabrics. The global MEG market represents a value of 25 billion dollars.
First production of isobutene from wheat straw at demo scale
New phase for the H2020 Optisochem project after 18 months of activity. Sugars from wheat straw produced at Clariant’s Sunliquid® pre-commercial plant have been shipped to Global Bioenergies’ Leuna demo plant. Successful test runs for production of straw-based isobutene, batches delivered to INEOS for evaluation
Cerbios-Pharma has approved the detailed design and budget for the installation in its High Potency Active Ingredients (HPAIs) dedicated building of a new production line able to accommodate larger volumes and batch size.
Cerbios is active in the HPAI arena since 1993 with an established expertise on handling Category 4 SafeBridge (OEL<10 ng/m3) Drug Substances in four different lines: 2 non cGMP ; 2 cGMP. The P5 building for larger scale cGMP production of HPAIs was originally conceived with empty spaces available for installing an additional production line.
The new production line will be Category 3 SafeBridge for batches ranging 5-30 kgs/ batch.
The new unit will be partially occupied for the manufacturing of an HPAI where larger volumes are required thus decreasing the production costs compared to the actual setup. The remaining capacity will be available for our CDMO services and partners.
“With 25 years of experience handling HPAIs, Cerbios’ reputation for its know-how and proficiency is bringing an increased number of partners’ projects for the development and manufacturing of clinical material as well as commercial production“, confirms Dr. Gabriel Haering, CEO. “Considering the conjugation suite for Antibody Drug Conjugates ready this summer and this new production line due in the second half of 2020, our offer to our partners will be six HPAI production units in a single site with space available for future expansions if needed”.
In fact, Cerbios supports its partners from the production of non cGMP batches needed for preclinical tests, through clinical to commercial supply applying state-of-the-art Project management system and Quality by Design approach that are paramount to the success of a production campaign and process evolution beyond the registration phase.